Dry Eye

Treatment requires a systematic, multifaceted approach to improve outcomes.

Selina McGee, OD, FAAO, emphasizes the significance of a multifactorial treatment approach for dry eye, especially in patients concurrently using other eye drops or contact lenses, and advocates for ocular sparing therapies when needed.

Selina McGee, OD, FAAO, reviews a challenging case involving a patient with advanced glaucoma on multiple medications, grappling with multifactorial dry eye.

Selina McGee, OD, FAAO, shares her comprehensive examination and treatment approach, underscoring the importance of tailoring treatments based on the individual's dry eye evaluation.

Selina McGee, OD, FAAO, presents a patient case referred for ocular surface optimization in preparation for cataract surgery.

John Sheppard, MD, explains the potential harm caused by over-the-counter artificial tears with preservatives on the ocular surface and discusses innovative ocular-sparing treatments that stimulate tear production.

John Sheppard, MD, reviews the case of a 63-year-old male with evaporative dry eye, facing challenges in managing his symptoms using over-the-counter artificial tears.

John Sheppard, MD, discusses the impact of continuous contact lens use on dry eye, often masking its signs, and explores treatment strategies for patients using contact lenses.

John Sheppard, MD, presents a dry eye case involving a 48-year-old female patient who has been using contact lenses for approximately three decades.

Physicians ask the right questions and take an aggressive approach to treatment.

Managing dry eye disease often is key to patient comfort.

Combining simple and advanced methods can lead to optimal patient outcomes.

Approaching dry eye disease holistically will empower patients to take charge with personalized home health solutions.

Proper management results in better expectations, outcomes for patients.

Prevent Blindness aims to educate the public on dry eye through free resources including fact sheets and social media graphics for Dry Eye Awareness Month.

The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.

Marjorie Rah, OD, PhD, FAAO, shares brief highlights from her 2023 AOA ePoster, "Clinical performance of unique preservative-free contact lens lubricating and rewetting drop."

Erich A. Hinel, OD, MS, FAAO, Dipl ABO, discusses the use of 3-layer amniotic membrames to treat severe keratoconjunctivitis sicca, severe dry eye, and ocular surface disease.

Shane Swatts, OD, reviewed the key points of his course on intense pulse light therapy.

Harmin Chima, OD, met with Optometry Times to discuss treatment options for ocular surface disease with Biovance's 3-layer amniotic membrane graft.

Ahmad M. Fahmy, OD, FAAO, Dipl ABO, gives highlights of his AOA 2023 poster that was a pooled analysis of the Gobi and Mojave studies relevant to perfluorohexyloctane (NOV03) for dry eye disease associated with Meibomian gland dysfunction.

This 3-pronged approach for nutritional intervention to help maintain dry eye disease is in addition to a recommended dietary intake of daily oily fish.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation, which covered 12 new treatments all optometrists should know about.

When dry eye treatments are not working for your patient’s symptoms or the anterior segment exam looks normal, you must ask yourself: What if the symptoms are secondary to a neurologic dysfunction in pain perception?

Bruder Healthcare expands their dry eye portfolio by entering a distribution agreement with AllerFocus for its Percutaneous Allergy Test.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation that discussed the pharmaceutical treatment of anterior segment inflammatory conditions.

Jessilin Quint, OD, MBA, MS, FAAO, shares the latest and greatest in the world of dry eye, from new technology to how clinicians can start in on dry eye therapy today.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

The water-free, preservative-free, anti-inflammatory drop from Novaliq, now coined Vevye, received FDA approval to treat the signs and symptoms of dry eye disease.

Since April 2022, the Dry Eye Foundation has been voicing concerns over the packaging of preservative-free drops as well as availability of noncompliant drops at online retailers.